

ECCO Guidelines on Inflammatory Bowel Disease and Malignancies

Hannah Gordon

Standards and Guidelines

IBD

December 18, 2022

This is the second European Crohn's and Colitis Organisation evidence-based consensus guideline on inflammatory bowel disease and malignancy, updating 2015 guidance to address cancer risk associated with IBD, cancer risk from IBD therapies, and IBD management in patients with active or recent cancer.

KEY POINTS

- The guideline addresses three key areas: the risk of cancers associated with inflammatory bowel disease itself, the risk of cancers from therapies used to treat inflammatory bowel disease, and the management of inflammatory bowel disease in patients with active or recent cancer.
- This consensus represents an update to previous European Crohn's and Colitis Organisation guidance published in 2015.
- The guideline is designed to inform management decisions where inflammatory bowel disease care intersects with malignancy risk or diagnosis.

VIEW THIS CONTENT ON GUTFLIX

<https://gutflifx.eu/search/d/0da7b07a-3dd3-11ef-9a04-0242ac140004>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.